1. Govoni, M, Hanly, JG. The management of neuropsychiatric lupus in the 21st century: still so many unmet needs? Rheumatology 2020; 59: v52–v62.
Google Scholar | Crossref | Medline2. Mak, A, Cheung, MW, Chiew, HJ, et al Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum 2012; 41: 830–839.
Google Scholar | Crossref | Medline | ISI3. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes . Arthritis Rheum 1999; 42: 599–608.
Google Scholar | Crossref | Medline4. Jeltsch-David, H, Muller, S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat Rev Neurol 2014; 10: 579–596.
Google Scholar | Crossref | Medline | ISI5. Khalil, M, Teunissen, CE, Otto, M, et al Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018; 14: 577–589.
Google Scholar | Crossref | Medline6. Trysberg, E, Nylen, K, Rosengren, LE, et al Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003; 48: 2881–2887.
Google Scholar | Crossref | Medline7. Tjensvoll, AB, Lauvsnes, MB, Zetterberg, H, et al Neurofilament light is a biomarker of brain involvement in lupus and primary Sjogren’s syndrome. J Neurol 2021; 268: 1385–1394.
Google Scholar | Crossref | Medline8. Aringer, M, Costenbader, K, Daikh, D, et al 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019; 71: 1400–1412.
Google Scholar | Crossref | Medline9. Kurki, P, Helve, T, Dahl, D, et al Neurofilament antibodies in systemic lupus erythematosus. J Rheumatol 1986; 13: 69–73.
Google Scholar | Medline10. Robbins, ML, Kornguth, SE, Bell, CL, et al Antineurofilament antibody evaluation in neuropsychiatric systemic lupus erythematosus. Combination with anticardiolipin antibody assay and magnetic resonance imaging. Arthritis Rheum 1988; 31: 623–631.
Google Scholar | Crossref | Medline11. Kuhle, J, Kropshofer, H, Haering, DA, et al Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 2019; 92: e1007–e1015.
Google Scholar | Crossref | Medline12. Tiedt, S, Duering, M, Barro, C, et al Serum neurofilament light: a biomarker of neuroaxonal injury after ischemic stroke. Neurology 2018; 91: e1338–e1347.
Google Scholar | Crossref | Medline13. Pawlitzki, M, Butryn, M, Kirchner, F, et al CSF Neurofilament light chain level predicts axonal damage in cerebral vasculitis. Ann Clin Transl Neurol 2019; 6: 1134–1137.
Google Scholar | Crossref | Medline14. Arkema, EV, Svenungsson, E, Von Euler, M, et al Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. Ann Rheum Dis 2017; 76: 1544–1549.
Google Scholar | Crossref | Medline15. Siller, N, Kuhle, J, Muthuraman, M, et al Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler 2019; 25: 678–686.
Google Scholar | SAGE Journals | ISI16. Uphaus, T, Bittner, S, Groschel, S, et al NfL (Neurofilament Light Chain) levels as a predictive marker for long-term outcome after ischemic stroke. Stroke 2019; 50: 3077–3084.
Google Scholar | Crossref | Medline17. Khalil, M, Pirpamer, L, Hofer, E, et al Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun 2020; 11: 812.
Google Scholar | Crossref | Medline18. Akamine, S, Marutani, N, Kanayama, D, et al Renal function is associated with blood neurofilament light chain level in older adults. Sci Rep 2020; 10: 20350.
Google Scholar | Crossref | Medline